Doximity Future Growth
Future criteria checks 1/6
Doximity is forecast to grow earnings and revenue by 9.7% and 9.8% per annum respectively. EPS is expected to grow by 11.9% per annum. Return on equity is forecast to be 16.9% in 3 years.
Key information
9.7%
Earnings growth rate
11.9%
EPS growth rate
Healthcare Services earnings growth | 0% |
Revenue growth rate | 9.8% |
Future return on equity | 16.9% |
Analyst coverage | Good |
Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 634 | 182 | 232 | 240 | 5 |
3/31/2026 | 575 | 162 | 224 | 234 | 13 |
3/31/2025 | 520 | 145 | 200 | 204 | 17 |
3/31/2024 | 474 | 137 | 181 | 190 | 17 |
12/31/2023 | 468 | 138 | 162 | 167 | N/A |
9/30/2023 | 448 | 123 | 160 | 165 | N/A |
6/30/2023 | 437 | 119 | 186 | 192 | N/A |
3/31/2023 | 419 | 113 | 173 | 180 | N/A |
12/31/2022 | 402 | 119 | 173 | 180 | N/A |
9/30/2022 | 384 | 141 | 151 | 159 | N/A |
6/30/2022 | 362 | 148 | 131 | 138 | N/A |
3/31/2022 | 344 | 133 | 121 | 127 | N/A |
12/31/2021 | 317 | 107 | 113 | 117 | N/A |
9/30/2021 | 277 | 57 | 110 | 114 | N/A |
6/30/2021 | 243 | 30 | 103 | 107 | N/A |
3/31/2021 | 207 | 22 | 78 | 83 | N/A |
12/31/2020 | 177 | 14 | 48 | 53 | N/A |
3/31/2020 | 116 | 11 | 22 | 26 | N/A |
3/31/2019 | 86 | 1 | 14 | 15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: D2OC34's forecast earnings growth (9.7% per year) is below the savings rate (9.9%).
Earnings vs Market: D2OC34's earnings (9.7% per year) are forecast to grow slower than the BR market (13.9% per year).
High Growth Earnings: D2OC34's earnings are forecast to grow, but not significantly.
Revenue vs Market: D2OC34's revenue (9.8% per year) is forecast to grow faster than the BR market (7.2% per year).
High Growth Revenue: D2OC34's revenue (9.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: D2OC34's Return on Equity is forecast to be low in 3 years time (16.9%).